Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to “Sell” at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Saturday.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Performance

NASDAQ MCRB opened at $0.84 on Friday. The firm has a market cap of $144.15 million, a price-to-earnings ratio of -3.67 and a beta of 2.13. The firm has a 50 day simple moving average of $0.83 and a 200-day simple moving average of $0.91. Seres Therapeutics has a one year low of $0.54 and a one year high of $1.53.

Institutional Trading of Seres Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC lifted its stake in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC raised its position in Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Seres Therapeutics during the 2nd quarter worth $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Seres Therapeutics during the 2nd quarter worth $92,000. Finally, State Street Corp increased its stake in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares during the period. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.